Results 231 to 240 of about 106,246 (275)

Analyses of plasma multi‐omic data across ancestries identify novel pathways implicated in Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Few genetic studies on Alzheimer's disease (AD) have incorporated multiple ancestries and omic datasets to pinpoint actionable AD risk effectors for each ancestry. METHODS Here, we first performed genetic colocalization between molecular phenotypes (proteomics and metabolomics) from two ancestral groups (European [EUR] and African
Chengran Yang   +9 more
wiley   +1 more source

Engineering Ultrasound Contrast Agents for Targeted Therapeutics: A Theranostic Approach to Drug Delivery, Gene Therapy, and Immunomodulation

open access: yesAdvanced NanoBiomed Research, Volume 6, Issue 2, February 2026.
Ultrasound contrast agents, including microbubbles and nanobubbles, transform imaging and targeted therapy through precise engineering of size, shell composition, and surface properties. This review explores how these innovations enable tissue‐specific delivery, enhance therapeutic efficacy, and extend applications from vascular imaging to tumor ...
Ashkan Seza   +2 more
wiley   +1 more source

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. [PDF]

open access: yesLeukemia, 2017
Alatrash G   +24 more
europepmc   +1 more source

An Overview of Liquid Chromatography–Mass Spectrometry (LC–MS) Methods for the Quantification of Antibody‐Drug Conjugates

open access: yesBiomedical Chromatography, Volume 40, Issue 2, February 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) are innovative drugs composed of cytotoxic molecules (payload) linked to antibodies, that selectively target and kill cancer cells upon internalization. In vivo, ADCs exist as intact molecules, naked antibodies, or released, unconjugated (linker‐)payload.
Pauline L. M. Buitelaar   +4 more
wiley   +1 more source

Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption

open access: yesComprehensive Physiology, Volume 16, Issue 1, February 2026.
Vildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Ratchaneevan Aeimlapa   +11 more
wiley   +1 more source

Proteomic Analysis of Regulated Dendritic Cell Endosomes Reveals Dynamic Adaptation to Antigen Uptake and Cross‐Presentation

open access: yesEuropean Journal of Immunology, Volume 56, Issue 2, February 2026.
Phagocytosis of yeast activates recruitment of proteases and trafficking factors from the secretory and endosomal pathways to the IRAP compartment and subsequently phagosomes, promoting cross‐presentation. In the absence of Sec22b, IRAP endosome and phagosome maturation to late endosomes is accelerated.
Alice Senni   +7 more
wiley   +1 more source

A two‐sample Mendelian randomization study and mediation analysis exploring the link between cathepsins and epilepsy

open access: yesEpilepsia Open, Volume 11, Issue 1, Page 78-88, February 2026.
Abstract Objective This study aims to investigate the causal relationship between cathepsins and epilepsy, using Mendelian randomization (MR) and mediation analysis. Methods Publicly accessible summary statistics on epilepsy were obtained from FinnGen and the International League Against Epilepsy Consortium.
Huaiyu Sun   +7 more
wiley   +1 more source

Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
ABSTRACT Background Bufalin is one main component of the dried venom from Bufo gargarizans Cantor, which has anti‐tumor, cardiotonic, anti‐inflammatory and other physiological activities. However, in recent years, researchers have mainly paid attention to its anti‐tumor effect and neglected its anti‐inflammatory effect.
Xixi Liu   +11 more
wiley   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies ...
Xiao‐Jian Zhou   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy